Kramer, Kim
Pandit-Taskar, Neeta
Kushner, Brian H.
Zanzonico, Pat
Humm, John L.
Tomlinson, Ursula
Donzelli, Maria
Wolden, Suzanne L.
Haque, Sophia
Dunkel, Ira
Souweidane, Mark M.
Greenfield, Jeffrey P.
Tickoo, Satish
Lewis, Jason S.
Lyashchenko, Serge K.
Carrasquillo, Jorge A.
Chu, Bae
Horan, Christopher
Larson, Steven M.
Cheung, Nai-Kong V.
Modak, Shakeel
Clinical trials referenced in this document:
Documents that mention this clinical trial
Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies
https://doi.org/10.1186/s13045-022-01383-4
Funding for this research was provided by:
National Institutes of Health (P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748)
Memorial Sloan-Kettering Cancer Center (Experimental Therapeutics Center)
Kallan's Klan
Article History
Received: 28 April 2022
Accepted: 15 August 2022
First Online: 12 November 2022
Declarations
:
: The conduct of this clinical trial was approved by the Memorial Sloan Kettering Institutional Review Board. Study patients or legal guardians provided written informed consent.
: Not applicable.
: MSK has institutional financial interests related to this research in the form of intellectual property rights and equity interests in Y-Mabs, the company licensing the intellectual property from MSK. N.K. Cheung (NKC) reports receiving commercial research grants from Y-Mabs Therapeutics and Abpro-Labs Inc.; holding ownership interest/equity in Y-Mabs Therapeutics Inc. and Abpro-Labs and owning stock options in Eureka Therapeutics. NKC and KK are inventors and owners of issued patents licensed by MSK to YMabs Therapeutics. KK holds ownership interest/equity in Y-Mabs Therapeutics Inc. NKC is a consultant/advisory board member for Abpro-Labs and Eureka Therapeutics. SM Larson (SML) reports: receiving commercial research grants from Genentech, Wilex, Telic and Regeneron; holding ownership interest/equity in Voreyda Theranostics Inc. and Elucida Oncology Inc.; holding stock in Imaginab. SML is the inventor and owner of issued patents both currently unlicensed and licensed by MSK to Samos Inc. and Elucida Oncology Inc. SML is or has been a consultant to Cynvec, Lilly, Prescient, Advanced Innovative Partners, Gershon Lehrman, Progenics and Janssen Pharmaceuticals. Jorge A Carasquillo reports other support from Y-Mabs Therapeutics. Mark M Souweidane reports other support from Aesculap. Kim Kramer, Serge Lyashchenko, and Shakeel Modak are consultants to Y-Mabs Therapeutics Inc. Shakeel Modak is a consultant to Illumina. Omburtamab was licensed to Y-Mabs Therapeutics by MSK in 2015. This clinical trial was not sponsored by Y-Mabs Therapeutics.